Neuroleptic maintenance medication is clearly effective for relapse prevention in schizophrenia, However, besides benefits for the majority of patients, there are also failures and/or risks for some patients (e.g. tardive dyskinesia). Since the risk-benefit ratio is often difficult to predict in the individual case, this has stimulated the search for modifications and alternatives to maintenance treatment. In particular, neuroleptic low-dose treatment strategies compare favorably with standard-dose treatment concerning relapse prevention and side effects. Alternatively, based on prodromal symptoms preceding a relapse, early intervention, intermittent neuroleptic treatment strategies have been developed. However, all recently completed controlled 2 year studies have not confirmed this strategy to be as effective as maintenance treatment in preventing relapse. Therefore, for the majority of patients intermittent treatment cannot be recommended.